{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:29:47Z","timestamp":1748914187264},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pierre Fabre Pharma GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12325-020-01430-x","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T02:02:46Z","timestamp":1594173766000},"page":"3619-3629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patients with BRAF-Mutant Advanced\/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice"],"prefix":"10.1007","volume":"37","author":[{"given":"Sebastian","family":"Haferkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen S.","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Haalck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid H.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"issue":"6","key":"1430_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"1430_CR2","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines): cutaneous melanoma. Version 1.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf. Accessed 2 Apr 2020."},{"issue":"10","key":"1430_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239\u201346.","journal-title":"J Clin Oncol"},{"key":"1430_CR4","unstructured":"Bericht zum Krebsgeschehen in Deutschland. 2016. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebsgeschehen\/Krebsgeschehen_node.html. Accessed 2 Apr 2020."},{"key":"1430_CR5","unstructured":"National Cancer Institute. SEER Cancer Statistics Review 1975-2014. 2020. https:\/\/surveillance.cancer.gov\/delay\/. Accessed 2 Apr 2020."},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2019.11.014","volume":"126","author":"C Garbe","year":"2020","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics\u2014update 2019. Eur J Cancer. 2020;126:141\u201358.","journal-title":"Eur J Cancer"},{"key":"1430_CR7","doi-asserted-by":"publisher","first-page":"102333","DOI":"10.1016\/j.jaut.2019.102333","volume":"104","author":"C Huang","year":"2019","unstructured":"Huang C, Zhu HX, Yao Y, et al. Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. J Autoimmun. 2019;104:102333.","journal-title":"J Autoimmun"},{"key":"1430_CR8","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in Immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75\u2013977.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3\u20134","key":"1430_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaut.2009.07.010","volume":"33","author":"JJ Subleski","year":"2009","unstructured":"Subleski JJ, Wiltrout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun. 2009;33(3\u20134):275\u201381.","journal-title":"J Autoimmun"},{"issue":"57","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671\u2013822.","journal-title":"Oncotarget"},{"issue":"10","key":"1430_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jclinpath-2019-206013","volume":"72","author":"V Kailashiya","year":"2019","unstructured":"Kailashiya V, Sharma HB, Kailashiya J. Role of CTLA4 A49G polymorphism in systemic lupus erythematosus and its geographical distribution. J Clin Pathol. 2019;72(10):659\u201362.","journal-title":"J Clin Pathol"},{"issue":"13","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-09-3064","volume":"16","author":"CA Pratilas","year":"2010","unstructured":"Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res. 2010;16(13):3329\u201334.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","volume":"399","author":"R Roskoski Jr","year":"2010","unstructured":"Roskoski R Jr. RAF protein-serine\/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399(3):313\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1430_CR14","first-page":"3362","volume":"9","author":"R Kumar","year":"2003","unstructured":"Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003;9(9):3362\u20138.","journal-title":"Clin Cancer Res"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-6-30","volume":"6","author":"T Huang","year":"2013","unstructured":"Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:30.","journal-title":"J Hematol Oncol"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1884\u2013901.","journal-title":"Ann Oncol"},{"key":"1430_CR17","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. 2020. https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.3322\/caac.21409. Accessed 17 Apr 2020."},{"issue":"6","key":"1430_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","volume":"29","author":"IP Silva","year":"2017","unstructured":"Silva IP, Long GV. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol. 2017;29(6):484\u201392.","journal-title":"Curr Opin Oncol"},{"issue":"16","key":"1430_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01430-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:38:56Z","timestamp":1659098336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01430-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01430-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}